Dr Lalchandani Labs Ltd
₹ 12.0
-0.08%
21 May
4:01 p.m.
About
Incorporated in 2011, Dr. Lalchandani Labs Ltd is in the business of running laboratories
for pathological investigations[1]
Key Points
- Market Cap ₹ 5.19 Cr.
- Current Price ₹ 12.0
- High / Low ₹ 28.9 / 0.00
- Stock P/E 12.4
- Book Value ₹ 23.0
- Dividend Yield 0.00 %
- ROCE 3.70 %
- ROE 4.31 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.52 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -3.60%
- The company has delivered a poor sales growth of -6.11% over past five years.
- Company has a low return on equity of -6.62% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 431 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 4.81 | 4.45 | |
2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.59 | 3.40 | |
Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.22 | 1.05 |
OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 4.57% | 23.60% |
0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.40 | 0.01 | |
Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.38 | 0.09 |
Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.62 | 0.56 |
Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | 0.62 | 0.41 |
Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | 0.00% | 0.00% | -2.44% |
0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | 0.62 | 0.42 | |
EPS in Rs | 0.89 | 1.22 | 1.08 | 2.33 | 2.15 | -3.60 | 1.43 | 0.97 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | -6% |
3 Years: | -27% |
TTM: | -7% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -2% |
3 Years: | -23% |
TTM: | 155% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 1% |
3 Years: | -32% |
1 Year: | -47% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 0% |
3 Years: | -7% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 2.93 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 |
Reserves | 0.40 | 3.73 | 4.21 | 5.22 | 6.15 | 4.59 | 5.21 | 5.62 |
1.88 | 0.90 | 1.76 | 4.04 | 5.15 | 6.40 | 3.48 | 4.07 | |
1.00 | 1.18 | 1.63 | 1.61 | 2.49 | 2.40 | 1.97 | 1.73 | |
Total Liabilities | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.75 |
2.06 | 3.28 | 3.47 | 5.24 | 5.75 | 5.39 | 3.99 | 3.51 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.41 | 0.27 |
3.91 | 6.62 | 8.22 | 9.72 | 12.13 | 12.09 | 10.59 | 11.97 | |
Total Assets | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.75 |
Cash Flows
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
0.58 | -0.45 | -0.10 | 1.19 | 2.01 | 0.00 | -0.22 | 0.44 | |
-1.29 | -1.95 | -0.53 | -2.26 | -1.53 | -0.20 | 1.00 | 0.06 | |
1.57 | 3.51 | 0.85 | 1.71 | 0.16 | -0.23 | -1.59 | 0.50 | |
Net Cash Flow | 0.85 | 1.12 | 0.23 | 0.64 | 0.64 | -0.43 | -0.81 | 1.00 |
Ratios
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 | 356.65 | 431.44 |
Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 | 255.15 | 490.47 |
Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 | 217.94 | 365.00 |
Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 | 393.86 | 556.91 |
Working Capital Days | 168.76 | 170.70 | 209.43 | 132.86 | 123.93 | 287.51 | 402.18 | 490.49 |
ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% | -2.68% | 3.70% |
Documents
Announcements
-
Integrated Filing (Financial)
2 May - Audited FY25 results with Rs.12.13L OTS gain; defaults on loans, statutory dues, and audit qualifications noted.
-
Board Meeting Outcome for Audited Financial Results For The Half Year And Year Ended March 31, 2025
1 May - Audited FY25 results with qualified audit, defaults on loans, unpaid dues, and one-time settlement gain Rs12.13L.
- Audited Financial Results For The Half Year And Year Ended March 31, 2025 1 May
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
30 Apr - Company states it is not a 'Large Corporate' per SEBI; borrowings under Rs. 1000 crore as of March 31, 2025.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Dr Lalchandani Labs confirms not a Large Corporate as of 31-Mar-2025 per SEBI norms.
Business Overview:[1][2][3]
DLLL is a NABL accredited company with 5 Self-sufficient Labs and 15 collection centers across Delhi/NCR. It is empaneled for CGHS (South, North and East Block), DJB, MCD, DDA etc. and provides diagnostic and related healthcare tests and services. Company owns, runs laboratories for carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.